US 11,866,441 B2
Compounds and methods for the treatment of parasitic diseases
Eamon Comer, Cambridge, MA (US); Nobutaka Kato, Cambridge, MA (US); Marshall Morningstar, Cambridge, MA (US); and Bruno Melillo, Cambridge, MA (US)
Assigned to THE BROAD INSTITUTE, INC., Cambridge, MA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Filed by THE BROAD INSTITUTE, INC., Cambridge, MA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Filed on Jul. 28, 2021, as Appl. No. 17/387,639.
Application 17/387,639 is a continuation of application No. 16/495,357, granted, now 11,174,260, previously published as PCT/US2018/023270, filed on Mar. 20, 2018.
Claims priority of provisional application 62/473,771, filed on Mar. 20, 2017.
Prior Publication US 2022/0162211 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); A61K 31/397 (2006.01); A61K 31/44 (2006.01); A61K 31/4406 (2006.01); A61P 33/00 (2006.01); A61P 33/02 (2006.01); A61P 33/06 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 33/06 (2018.01)] 19 Claims
 
1. A compound having the structure:

OG Complex Work Unit Chemistry
R1 is optionally substituted aryl or heteroaryl;
R2 is optionally substituted alkoxy, cycloalkoxy or heterocyclyl;
R3 is hydrogen, or —CH2—X;
R4 and R5 are independently hydrogen, —X, or —CH2—X, and at least one of R4 and R5 is not hydrogen;
—X is independently selected at each occurrence from —OH, —OR, —S(O)R, —S(O)2R, —N(R)—S(O)2R, —S(O)2—N(R)(R), —S(O)2—NHR, —N(R)—C(O)—R, —NH2, or —N(R)(R); and
R is independently at each occurrence an optionally substituted C1-C12 alkyl;
or a pharmaceutically acceptable salt thereof.